Pharma Journalist -

Enlaza Therapeutics, the first covalent biologic platform company, announced a $100 million Series A financing. The financing will be used to further develop Enlaza’s proprietary…
Read More...

Neurocrine Biosciences, Inc. announced the U.S. Food and Drug Administration has approved INGREZZA SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA…
Read More...

Merck, a leading science and technology company, is investing more than € 300 million in a new research center at its global headquarters in Darmstadt, Germany. In the Advanced Research…
Read More...

Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc., announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple…
Read More...

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Lutathera (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of…
Read More...

Incyte and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders,…
Read More...

Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients…
Read More...

Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological…
Read More...

Ochre Bio, a pioneer in chronic liver disease medicine development, announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class…
Read More...

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO (aztreonam-avibactam) for the treatment of adult patients with complicated…
Read More...